Arcturus to Develop ARCT-032 as RNA Therapy for CF

Arcturus to Develop ARCT-032 as RNA Therapy for CF

281708

Arcturus to Develop ARCT-032 as RNA Therapy for CF

Arcturus Therapeutics has selected ARCT-032, an aerosolized RNA-based therapy, to be developed as a novel therapeutic candidate for cystic fibrosis (CF). The therapy will use the company’s LUNAR delivery technology that comprises a library of more than 150 proprietary fatty molecules specifically designed to deliver RNA-based therapies to a particular cell type of interest, according to Arcturus. In the case of ARCT-032, LUNAR will be employed to deliver an aerosolized form of the therapy, which…

You must be logged in to read/download the full post.